Most clinic ads are breaking this rule

There's a pattern in the ASA's weight-loss ad rulings that most clinic marketers haven't noticed.

Since early 2025, the Advertising Standards Authority has been running targeted enforcement on ads for prescription-only weight-loss medicines. The results are public, the rulings are accumulating, and the number of clinics caught in this net is growing.

Here's what it means for your clinic's advertising.

Here's what you need to know.

What the ASA is actually enforcing

In April 2026, the ASA published an enforcement report that showed the scale of the issue. Their Active Ad Monitoring system captured and analysed over 95,000 unique paid online ads from 44 advertisers across Google, Meta, TikTok, and display advertising. Around 35,000 of those related to weight management services.

Roughly 900 ads from 38 advertisers were assessed as likely breaking the rules. The main issues: naming prescription-only medicines, wording that implied them, and images of branded injection pens.

But it's the specific upheld rulings that tell the real story.

Juniper: Black Friday Instagram ads for Mounjaro

In April 2026, the ASA upheld a ruling against Juniper Technologies UK Ltd (trading as Juniper), an online pharmacy. The ads were paid Instagram promotions offering Black Friday discounts on weight-loss medication.

One ad stated: "Medicated weight loss starting from £85, now that's a Black Friday discount." Another used the headline: "6 months of weight loss medication, 1 Black Friday discount."

The ASA found two breaches: advertising a prescription-only medicine (POM) to the public, and creating undue urgency through a time-limited offer. Both were upheld.

Voy: Black Friday email campaigns for Wegovy

A month later, the ASA upheld a ruling against Menwell Ltd (trading as Voy). Three Black Friday email promotions pushed Wegovy and tirzepatide weight-loss programmes with countdown timers and urgency language.

One email featured an image of a branded Wegovy injection pen with a detached cap. Another stated: "Last day to save Up to £70 OFF all plans."

Again, two breaches upheld: POM advertising and social irresponsibility for pressuring consumers with time-limited discounts on prescription medication.

The enforcement report: 99% compliance — eventually

The ASA's enforcement report shows the trajectory. When monitoring began in February 2025, 7% of ads were likely breaching POM rules. After the first Enforcement Notice in April 2025, that fell to 4%. After a second notice in September 2025, it dropped to 1%.

By January 2026, compliance reached 99%. CAP contacted 46 advertisers. All but one either amended or removed their ads. That single non-respondent was referred to the General Pharmaceutical Council (GPhC) for potential regulatory action.

The rule most marketers miss

The rule at the centre of these rulings is CAP Code rule 12.12. It says: "Prescription-only medicines (POMs) must not be advertised to the public."

It sounds simple. But most clinic marketers think they're fine as long as they don't name the drug. The ASA rulings show enforcement goes deeper than that.

The Juniper ads never named Mounjaro. They used the phrase "medicated weight loss." The ASA considered that wording implied a POM — because weight-loss medication available through an online pharmacy is, by definition, prescription-only. The indirect reference was enough.

The Voy ads did name Wegovy explicitly. They also showed a branded injection pen. That is a textbook POM breach. But the ASA went further — it also ruled that countdown timers and "offer ends soon" language created undue pressure on consumers to make a medical decision under time constraints.

This matters because the combination is what catches clinics. You can avoid naming the drug and still breach the rules if your wording implies a prescription medicine is available. And you can avoid implying a POM and still breach under social responsibility rules if your ad creates urgency around a medical treatment.

Here's what the ASA considers when evaluating whether an ad breaches POM rules:

• Naming a POM — even in a product name, URL, or image alt text
• Showing branded packaging or injection devices — a Wegovy pen, a Mounjaro box, a branded vial
• Using language that implies prescription medication — "medicated weight loss," "clinician-prescribed," "doctor-supervised weight loss injections"
• Referencing specific clinical outcomes associated with a named POM — "lose 15% of your body weight" when that figure matches a specific drug trial result
• Using generic injection or medication imagery — a syringe or injection pen in a weight-loss context

The Human Medicines Regulations 2012 provide the statutory basis. Rule 12.12 of the CAP Code operationalises it for advertising. Together, they create a framework that catches far more ads than most marketers expect.

What this means for your clinic's advertising

If your clinic or online pharmacy advertises weight-loss services, the practical implications are clear.

What to check in your own ads

Start with your current campaigns. If you are running Google Ads, Meta ads, TikTok promotions, or email campaigns that mention weight-loss medication — even indirectly — review each one against the ASA's recent rulings.

Particular red flags:

• Any image of an injection pen, syringe, or branded medication packaging
• Phrases like "medical weight loss," "medicated weight loss," "prescription weight loss," or "clinician-prescribed treatment"
• Time-limited offers, countdown timers, or urgency language applied to medication
• Price promotions that reference treatment plans involving POMs
• Discount codes for medication-based programmes

What the ASA considers acceptable

The enforcement report shows that 99% of advertisers achieved compliance after clear guidance. The ASA is not looking to punish — it is looking to educate. But the process is public, and each upheld ruling creates a permanent record that patients, competitors, and journalists can find.

Compliant weight-loss service ads typically:

• Focus on the service and consultation, not the medication
• Use language like "weight management programme" or "weight loss consultation"
• Make clear that treatment is subject to clinical assessment
• Avoid any imagery that suggests a specific medication
• Do not include time-limited offers or pressure tactics

The GPhC dimension

The enforcement report is not the only regulatory pressure on weight-loss clinics. In April 2026, the GPhC published a major review of weight management services, analysing inspection reports from January 2024 to December 2025. The findings identified weaknesses in risk assessments, patient consultation records, BMI verification processes, and clinical follow-up arrangements.

Combined with the ASA's advertising enforcement, this means online pharmacies face pressure on two fronts: what you say in your ads, and how you deliver the service behind them.

What to watch next

The ASA's monitoring programme is ongoing. The enforcement report makes clear that the regulator will continue using its Active Ad Monitoring system to scan paid ads across major platforms. Compliance is at 99% now, which means the remaining 1% — and any new entrants — will be visible targets.

The GPhC review signals that inspections of weight-management services will continue with heightened scrutiny. The ASA referral pathway to the GPhC means advertising breaches can escalate beyond a published ruling into professional regulation.

CheckMyClinic has tracked every ASA ruling on weight-loss medicine advertising since 2023. The pattern is clear: enforcement is active, the rules are broader than most marketers realise, and the consequences extend beyond having an ad removed.

We're tracking this. Subscribe for weekly regulatory updates as the enforcement landscape evolves.